Connor, Clark & Lunn Investment Management (CC&L)
VNDA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Vanda Pharmaceuticals VNDA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
215,206
-161,652
-43% -$1.06M ﹤0.01% 1119
2026
Q1 		$2.6M Sell
376,858
-366,688
-49% -$2.83M 0.01% 879
2025
Q4 		$6.56M Sell
743,546
-160,998
-18% -$886K 0.02% 573
2025
Q3 		$4.51M Buy
904,544
+36,125
+4% +$167K 0.01% 599
2025
Q2 		$4.1M Sell
868,419
-61,225
-7% -$268K 0.01% 635
2025
Q1 		$4.27M Buy
929,644
+110,262
+13% +$514K 0.02% 536
2024
Q4 		$3.92M Buy
819,382
+38,449
+5% +$185K 0.02% 550
2024
Q3 		$3.66M Buy
780,933
+55,567
+8% +$298K 0.02% 514
2024
Q2 		$4.1M Buy
725,366
+32,488
+5% +$168K 0.02% 470
2024
Q1 		$2.85M Buy
692,878
+427,429
+161% +$1.71M 0.01% 576
2023
Q4 		$1.12M Hold
265,449
– – 0.01% 830
2023
Q3 		$1.15M Hold
265,449
– – 0.01% 779
2023
Q2 		$1.75M Buy
265,449
+41,299
+18% +$265K 0.01% 642
2023
Q1 		$1.52M Buy
224,150
+5,342
+2% +$37.6K 0.01% 620
2022
Q4 		$1.62M Buy
218,808
+99,878
+84% +$973K 0.01% 599
2022
Q3 		$1.18M Buy
118,930
+49,382
+71% +$521K 0.01% 618
2022
Q2 		$758K Buy
+69,548
New +$721K ﹤0.01% 682
2020
Q3 		– Sell
-42,341
Closed -$484K – 1135
2020
Q2 		$484K Buy
+42,341
New +$479K ﹤0.01% 762
2016
Q2 		– Sell
-25,300
Closed -$212K – 937
2016
Q1 		$212K Sell
25,300
-58,700
-70% -$482K ﹤0.01% 707
2015
Q4 		$782K Sell
84,000
-5,900
-7% -$58.9K 0.01% 478
2015
Q3 		$1.01M Buy
+89,900
New +$1.1M 0.01% 396
2015
Q2 		– Sell
-18,900
Closed -$176K – 662
2015
Q1 		$176K Sell
18,900
-17,000
-47% -$192K ﹤0.01% 513
2014
Q4 		$514K Buy
+35,900
New +$425K ﹤0.01% 387
2014
Q2 		– Sell
-144,707
Closed -$2.6M – 641
2014
Q1 		$2.6M Buy
144,707
+68,907
+91% +$980K 0.02% 243
2013
Q4 		$999K Buy
75,800
+7,600
+11% +$76.3K 0.01% 368
2013
Q3 		$768K Buy
68,200
+44,400
+187% +$474K 0.01% 300
2013
Q2 		$203K Buy
+23,800
New +$160K ﹤0.01% 471

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VNDA Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Vanda Pharmaceuticals (VNDA) stake by 43% in Q2 2026, selling an estimated $1.06M and leaving 215,206 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VNDA in Q2 2013 and has held it in 27 quarters since. The position peaked at $6.56M in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 215,206 shares of Vanda Pharmaceuticals worth $1.32M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 161,652 Vanda Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
  • Vanda Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1119 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Vanda Pharmaceuticals position peaked at $6.56M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.